An interventional study of Ambulatory Holter monitoring and Discontinuous monitoring in Atrial Fibrillation, Ischemic Stroke and Transient Ischemic Attack, sponsored by Ewha Womans University Mokdong Hospital. Terminated at 7 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Ewha Womans University Mokdong Hospital · Not applicable, Interventional, and Screening
Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.
Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 66th largest by enrollment of the 144 interventional ones that give a count, is one of 12 that started in 2020, is one of 91 with no phase, and was the 127th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
Oslo University Hospital · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 22 · Phase 4 22
First in 2005; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 338 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 300 across the 144 interventional studies, 1,181 across the 65 observational. Of the 101 that completed or were terminated, 33 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 209 have an industry lead sponsor. The 10 most frequent:
Ewha Womans University Mokdong Hospital is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Ewha Womans University Mokdong Hospital has 8 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
11 of the studies in Atrial Fibrillation with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07641582Seoul St. Mary's HospitalPrediction of Atrial Fibrillation Using Polygenic Risk Score | 2026-12-30 |
| NCT05507749Seoul National University HospitalCyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring | 2026-12-31 |
| NCT07947498Chungnam National University HospitalPrognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction | 2026-12-31 |
| NCT05794386Seoul National University HospitalSCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) detected after ischemic stroke has immediate therapeutic implications, because it prompts a switch from antiplatelet to anticoagulant therapy. The conventional method used to screen for AF in patients whose stroke has no identified cause (cryptogenic stroke) is 24-hour Holter monitoring. CANDLE-AF is a multicenter, open-label, randomized trial comparing three noninvasive monitoring strategies over 12 months in patients with cryptogenic ischemic stroke or transient ischemic attack and no known AF: physician-directed standard care (at least one 24- to 72-hour Holter recording), scheduled 72-hour single-lead patch ECG monitoring repeated at 1, 3, 6, and 12 months, and twice-daily 30-second handheld single-lead ECG recording with a smartphone-based device for 12 months. The primary outcome is detection of AF lasting 30 seconds or longer within 12 months.
The criteria were revised on the registry on Sep 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physician-directed standard care, including at least one 24- to 72-hour Holter recording; further rhythm monitoring during the 12-month follow-up at the treating physician's discretion. Anticoagulation is recommended when AF is detected, at the treating physician's discretion.
Device: Ambulatory Holter monitoring
Standard care plus twice-daily 30-second single-lead ECG recordings with a smartphone-based handheld recorder (KardiaMobile, AliveCor) for 12 months, transmitted through the smartphone application to a cardiac core laboratory. Anticoagulation is recommended when AF is detected, at the treating physician's discretion.
Device: Ambulatory Holter monitoring · Device: Discontinuous monitoring
Standard care plus continuous 72-hour single-lead adhesive patch ECG monitoring (mobiCARE-MC100, Seers Technology) at 1, 3, 6, and 12 months after enrollment, transmitted to a cardiac core laboratory. Anticoagulation is recommended when AF is detected, at the treating physician's discretion.
Device: Ambulatory Holter monitoring · Device: Continuous single-lead ECG Patch
At least one 24- to 72-hour ambulatory Holter recording; additional monitoring at the physician's discretion.
Also known as: Standard care
Twice-daily 30-second handheld single-lead ECG recording for 12 months.
Also known as: iECG, Kardiamobile
72-hour continuous single-lead patch ECG monitoring at 1, 3, 6, and 12 months (four sessions)
Also known as: Patch monitoring, Mobicare, mobiCARE-MC100
Detection of atrial fibrillation lasting 30 seconds or longer
First detection of AF lasting at least 30 seconds on any ECG recording (assigned device, Holter, 12-lead ECG, or clinical recording), confirmed by physician review
Time frame: Within 12 months after randomization
Recurrent ischemic stroke or transient ischemic attack
Time frame: Within 12 months after randomization
Major adverse cardiovascular and cerebrovascular events (MACCE)
composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death
Time frame: Within 12 months after randomization
Initiation of oral anticoagulation following AF detection
Initiation of oral anticoagulation following AF detection
Time frame: Within 12 months after randomization
All-cause readmission
Time frame: Within 12 months after randomization
All-cause death
All-cause death
Time frame: Within 12 months after randomization
Major bleeding
Fatal or overt bleeding with a drop in hemoglobin level of at least 2 g/dL or requiring transfusion of at least 2 units packed blood cells, or critical anatomical site hemorrhage (e.g., intracranial, retroperitoneal)
Time frame: Within 12 months after randomization
Plan to share: Yes — De-identified individual participant data underlying the published results, a data dictionary defining each field, and the statistical analysis code will be made available to qualified investigators.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 12 months after publication of the primary results, with no end date
Access criteria: Requests with a methodologically sound proposal should be directed to the corresponding author (parkjb@ewha.ac.kr). Access requires approval by the institutional review board of Ewha Womans University Medical Center and a signed data access agreement; data will be shared only for analyses within the scope of the informed consent.
No publications or documents are linked to this record.
Ran from Nov 2020 to primary completion in Jul 2026, 67 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2025 → Jul 2026 and completion Nov 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.
Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ewha Womans University Mokdong Hospital